Alzheimer’s Association International Conference 2026
12 – 15 July 2026
London, UK
Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
About
We are creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs® and TRIMGLUEs®, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorders.
Team
Led by a team of world-renowned scientists, experienced entrepreneurs and pharma and biotech executives with a proven track record of developing innovative technologies and novel therapeutics.
Science
Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.
Latest News
Events
Oncology & Immunology Innovation Partnering & Licensing Summit
9 -10 September 2026
Boston
© TRIMTECH Therapeutics
TRIMTAC, TRIMVEC and TRIMGLUE are registered trademarks of TRIMTECH Therapeutics Ltd.
